AR060312A1 - Metodos para regular renalasa (monoamina oxidasa c) - Google Patents

Metodos para regular renalasa (monoamina oxidasa c)

Info

Publication number
AR060312A1
AR060312A1 ARP060105101A ARP060105101A AR060312A1 AR 060312 A1 AR060312 A1 AR 060312A1 AR P060105101 A ARP060105101 A AR P060105101A AR P060105101 A ARP060105101 A AR P060105101A AR 060312 A1 AR060312 A1 AR 060312A1
Authority
AR
Argentina
Prior art keywords
renalase
methods
protein
monoamine oxidase
regulate
Prior art date
Application number
ARP060105101A
Other languages
English (en)
Inventor
Gary Desir
Jianchao Xu
Original Assignee
Univ Yale
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Yale filed Critical Univ Yale
Publication of AR060312A1 publication Critical patent/AR060312A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C12N9/0012—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.6, 1.7)
    • C12N9/0014—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.6, 1.7) acting on the CH-NH2 group of donors (1.4)
    • C12N9/0022—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.6, 1.7) acting on the CH-NH2 group of donors (1.4) with oxygen as acceptor (1.4.3)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/44—Oxidoreductases (1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y104/00—Oxidoreductases acting on the CH-NH2 group of donors (1.4)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychiatry (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Urology & Nephrology (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Métodos para usar monoamina oxidasa C (MAO-C), también conocida como renalasa, como proteína terapéutica en sus formas activa e inactiva. Se puede usar la administracion de proteína renalasa inactiva a individuos con bajos niveles de renalasa para suministrarles un deposito adecuado de la proteína que pueda ser activado por el cuerpo cuando lo necesita. La proteína renalasa activa se puede administrar a individuos que necesitan una reduccion inmediata de los niveles de catecolaminas. Se puede usar un inhibidor de renalasa para aumentar la accion adrenérgica.
ARP060105101A 2005-11-21 2006-11-21 Metodos para regular renalasa (monoamina oxidasa c) AR060312A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US73849405P 2005-11-21 2005-11-21

Publications (1)

Publication Number Publication Date
AR060312A1 true AR060312A1 (es) 2008-06-11

Family

ID=38048981

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP060105101A AR060312A1 (es) 2005-11-21 2006-11-21 Metodos para regular renalasa (monoamina oxidasa c)

Country Status (8)

Country Link
US (2) US7858084B2 (es)
EP (1) EP1951291A4 (es)
JP (1) JP2009516693A (es)
AR (1) AR060312A1 (es)
AU (1) AU2006315299A1 (es)
CA (1) CA2630085A1 (es)
TW (1) TW200738255A (es)
WO (1) WO2007059357A1 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2559211A1 (en) * 2004-03-19 2005-09-29 Yale University Detection, isolation and uses of renalase (monoamine oxidase c)
WO2008091408A2 (en) * 2006-09-25 2008-07-31 Yale University Circulating renalase and methods of increasing same
WO2012135848A2 (en) * 2011-04-01 2012-10-04 Scott & White Healthcare Melatonin-based treatment and diagnosis of bile duct disease
EP2872166B1 (en) * 2012-07-16 2021-09-08 Yale University Compositions and methods for detecting, treating and preventing diseases and disorders
US10273311B2 (en) * 2014-06-26 2019-04-30 Yale University Compositions to regulate renalase in the treatment of diseases and disorders
CA3087059A1 (en) * 2017-12-29 2019-07-04 Yale University Anti-renalase antibodies for the treatment and prevention of diseases and disorders

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5932465A (en) 1997-10-16 1999-08-03 Icos Corporation Phosphodiesterase 8A
CA2333917A1 (en) 1998-07-15 2000-01-27 Human Genome Sciences, Inc. 71 human secreted proteins
EP1074617A3 (en) 1999-07-29 2004-04-21 Research Association for Biotechnology Primers for synthesising full-length cDNA and their use
CA2379998A1 (en) 1999-08-04 2001-02-15 Pharmacia & Upjohn Company Soluble, active recombinant human mao-b
AU2001234944A1 (en) 2000-02-03 2001-08-14 Hyseq, Inc. Novel nucleic acids and polypeptides
EP1356092A2 (en) 2000-05-26 2003-10-29 Corixa Corporation Compositions and methods for the therapy and diagnosis of ovarian cancer
AU2002255478A1 (en) 2001-01-10 2002-09-12 Pe Corporation (Ny) Kits, such as nucleic acid arrays, comprising a majority of human exons or transcripts, for detecting expression and other uses thereof
US20040005685A1 (en) 2002-06-05 2004-01-08 Millennium Pharmaceuticals, Inc. 97316, a human amine oxidase family member and uses therefor
CA2559211A1 (en) * 2004-03-19 2005-09-29 Yale University Detection, isolation and uses of renalase (monoamine oxidase c)
US20060286078A1 (en) 2005-06-15 2006-12-21 Humes H D Methods of treating cardiorenal syndrome and hepatorenal syndrome

Also Published As

Publication number Publication date
TW200738255A (en) 2007-10-16
US7858084B2 (en) 2010-12-28
CA2630085A1 (en) 2007-05-24
AU2006315299A1 (en) 2007-05-24
WO2007059357A1 (en) 2007-05-24
JP2009516693A (ja) 2009-04-23
EP1951291A4 (en) 2012-04-04
EP1951291A1 (en) 2008-08-06
US20110081421A1 (en) 2011-04-07
US20070248585A1 (en) 2007-10-25

Similar Documents

Publication Publication Date Title
CL2008003653A1 (es) Uso de un inhibidor de sglt derivado de glucopiranosilo y un inhibidor de dppiv seleccionado para tratar la diabetes; y composicion farmaceutica.
CL2016002589A1 (es) Uso del compuesto genz-112638 (eliglustat), inhibidor de glucosilceramida sintasa, en el tratamiento de la enfermedad de gaucher y enfermedad de fabry (divisional de solicitud 201201348).
AR109605A2 (es) Método para tratar enfermedades vasculares periféricas, composición y utilización
DOP2006000008A (es) Terapia combinada para el tratamiento de la diabetes y afecciones relacionadas y para el tratamiento de afecciones que mejoran mediante un incremento de la concentración sanguínea de glp-1
AR060306A1 (es) Terapia de combinacion de anticuerpos contra ctla4
AR044007A1 (es) Metodos para el tratamiento de la enfermedad de parkinson
AR060312A1 (es) Metodos para regular renalasa (monoamina oxidasa c)
CL2008003901A1 (es) Uso de un inhibidor de hedgehog para extender la sobrevida libre de recidiva en un paciente con cancer, que se encuentra en quimioterapia o ha sido tratado previamente con quimioterapia.
PA8637201A1 (es) Difenilimidazopirimidina e-imidazol aminas como inhibidores de la b-secretasa
EA201101187A1 (ru) Антидиабетические лекарственные средства, содержащие ингибитор dpp-4 (линаглиптин) необязательно в комбинации с другими антидиабетическими средствами
GT200800250A (es) Arilimidazolonas y ariltriazolonas sustituidas como inhibidores de receptores de vasopresina
ES2674129T3 (es) Agentes terapéuticos de base aptámeros útiles en el tratamiento de trastornos relacionados con complemento
AR054909A1 (es) Modulacion de los receptores activados por el proliferador de peroxisomas
AR078346A1 (es) Anticuerpos humanos de alta afinidad contra el receptor activado por proteasa de tipo 2 humano
SV2006002131A (es) Uso de un anticuerpo para el tratamiento de lupus
ECSP11010824A (es) Tratamiento para diabetes en pacientes inapropiados para terapia con metformina.
PA8631801A1 (es) Tratamiento de la hemorragia de disrupcion en regimenes anticonceptivos extendidos
DOP2011000188A (es) Compuestos de tiazolopiridinas moduladores de sirtuina
NO20073033L (no) Cytotoksiske midler innbefattende nye taksaner
UY29274A1 (es) Composicion farmaceutica para tratar la hipertension, que comprende telmisartano e hidroclorotiazida
NI200800176A (es) Uso de derivados de sulfamidas heterocíclicas benzo-fusionadas para el tratamiento de la depresión
CL2009000803A1 (es) Uso de una variante de igf-1 pegilada para tratar, prevenir un trastorno neuromuscular; metodo para el tratamiento, prevencion y/o demora de un trastorno neuromuscular; composicion que comprende la variante de igf-1 modificada
CL2004000366A1 (es) USO DE UNA COMBINACION DE UN COMPUESTO DERIVADO DE PIRAZOL INHIBIDOR DE QUINASA p38, Y UN INHIBIDOR DE ACE PARA TRATAR DISFUNCION RENAL, ENFERMEDAD CARDIOVASCULAR Y VASCULAR, RETINOPATIA, NEUROPATIA, EDEMA, DISFUNCION ENDOTELIAL O INSULINOPATIA.
AR058173A1 (es) Uso de sdf-1 para el tratamiento y/o prevencion de enfermedades neurologicas
CL2013003307A1 (es) Agente que comprende ciazofamida o fenamidona; y su uso para tratar micosis en peces e invertebrados en todos sus estadios de desarrollo causada por hongos de los generos saprolegnia, achlya y aphanomyces (div.sol.n°1056-08).

Legal Events

Date Code Title Description
FA Abandonment or withdrawal